Andrew Left, owner and founder of Citron Research, stands for a... Nachrichtenfoto - Getty Images
Watch Safkhet Capital's Quadir Is Still Short Valeant - Bloomberg
Valeant Short Seller Dials Back Warning of Bombshell Report on Monday - WSJ
The 'Short' Who Sank Valeant Stock - WSJ
What the Average Short Position in Valeant
Short Seller Famous for Bet Against Valeant Targets Tesla
The Valeant saga: Why the world needs short sellers
Famed short-seller Chanos can't cash in on Valeant
Hacked Printers. Fake Emails. Questionable Friends. Fahmi Quadir Was Up 24% Last Year, But It Came at a Price. | Institutional Investor
Jim Chanos: I'm still short Valeant and not about to quit
Valeant 'short' smells smoke — even when there's no fire
Die Shortsellerin, die schon 2018 gegen Wirecard wettete - Capital.de
What the Average Short Position in Valeant
Valeant's stock has plunged, so where are all the shorts? - The Globe and Mail
The Anti-Ackman: Valeant Short Sellers Have Made $2.8 Billion - Bloomberg
Citron Short Valeant Again
Valeant shares plunge after 'fraud' accusation from short-seller | CBC News
Valeant Pharmaceuticals Cuts Earnings and Sales Forecasts - The New York Times
Opinion: Time to short Valeant bonds, go long its stock - MarketWatch
Valeant scandal shows why we need short-sellers in the stock market - Los Angeles Times
The rise and fall of Valeant Pharmaceuticals | CBC News
Valeant Plunges 30% After Short Seller Citron Research Makes Fraud Allegation
Valeant: Just Short It (NYSE:BHC) | Seeking Alpha
Valeant: Preispoker mit Medikamenten
